Q1 Earnings Forecast for ADAP Issued By HC Wainwright

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Adaptimmune Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst A. He expects that the biotechnology company will earn ($0.18) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $3.50 target price on the stock. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.12) EPS.

Separately, StockNews.com cut Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday.

Adaptimmune Therapeutics Stock Down 23.3 %

Shares of NASDAQ:ADAP opened at $0.59 on Friday. Adaptimmune Therapeutics has a 52-week low of $0.42 and a 52-week high of $2.05. The stock has a market cap of $151.19 million, a P/E ratio of -1.69 and a beta of 2.26. The business’s 50 day moving average is $0.89 and its 200 day moving average is $1.04. The company has a quick ratio of 3.09, a current ratio of 3.09 and a debt-to-equity ratio of 0.26.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter. Adaptimmune Therapeutics had a negative return on equity of 116.80% and a negative net margin of 51.25%. The company had revenue of $128.23 million for the quarter, compared to analysts’ expectations of $58.00 million.

Institutional Trading of Adaptimmune Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ADAP. FMR LLC boosted its position in shares of Adaptimmune Therapeutics by 3.0% in the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after purchasing an additional 50,419 shares in the last quarter. Baillie Gifford & Co. boosted its position in shares of Adaptimmune Therapeutics by 10.7% in the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock worth $15,944,000 after purchasing an additional 1,626,657 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Adaptimmune Therapeutics in the 3rd quarter worth $95,000. Fullcircle Wealth LLC acquired a new stake in shares of Adaptimmune Therapeutics in the 3rd quarter worth $33,000. Finally, Vontobel Holding Ltd. boosted its position in shares of Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 30,000 shares in the last quarter. Institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.